Hepion pharmaceuticals, inc. granted 180-day extension by nasdaq to meet the minimum bid price requirements

Edison, n.j., dec. 05, 2022 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic diseases, announced that is has received written notification from the listing qualifications department of the nasdaq stock market llc ("nasdaq") granting the company's request for a 180-day extension to regain compliance under the nasdaq listing rule 5550(a)(2). the company now has until may 30, 2023, to meet the requirement.
HEPA Ratings Summary
HEPA Quant Ranking